How many clinical trials are studying Goserelin?

9 recruiting trials in our tracked data involve Goserelin.

What conditions is Goserelin being studied for?

In our tracked recruiting trials, Goserelin is being studied in trials for Breast Cancer, Breast Neoplasm, Breast Neoplasms.

Goserelin: clinical trials recruiting now

Q: Is Goserelin FDA-approved?

Yes. According to the FDA drug label available through openFDA, Goserelin is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Goserelin appears in the FDA drug-label database. Marketed as ZOLADEX.

FDA-approved use

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic l…

FDA label via openFDA

Phase breakdown

Phase 2 8 Phase 3 1

Conditions being studied

Condition	Trials
Breast Cancer · Goserelin for Breast Cancer	8
Breast Neoplasm	2
Breast Neoplasms	2
HER2-negative Breast Cancer	2
HER2-positive Breast Cancer	2
Hormone Receptor Positive Tumor	2
Advanced Breast Cancer	1
Anatomic Stage I Breast Cancer AJCC v8	1
Anatomic Stage II Breast Cancer AJCC v8	1
Anatomic Stage III Breast Cancer AJCC v8	1
Anatomic Stage IV Breast Cancer AJCC v8	1
Biochemically Recurrent Prostate Carcinoma	1
Breast Tumors	1
Cancer of Breast	1
Cancer of the Breast	1

Recruiting trials involving Goserelin

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 89 locations
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
NCT06348134 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 4 locations
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT02476786 · Phase: Phase 2 · Ages: 70 Years and older · Sex: Female · 1 location
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
NCT05720260 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 1 location
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT07158021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 229 locations
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
NCT06378866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations

Common questions

Is Goserelin FDA-approved?

Yes, marketed as ZOLADEX.

How many recruiting trials involve Goserelin?

9 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.